Get the Stockscreener App
3.52
0.00%
0.00
After Hours:
3.51
-0.01
-0.28%
Aquestive Therapeutics Inc stock is traded at $3.52, with a volume of 913.99K.
It is up +0.00% in the last 24 hours and down -30.84% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
See More
Previous Close:
$3.52
Open:
$3.51
24h Volume:
913.99K
Relative Volume:
0.63
Market Cap:
$320.95M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-7.8222
EPS:
-0.45
Net Cash Flow:
$-24.91M
1W Performance:
-1.95%
1M Performance:
-30.84%
6M Performance:
+35.38%
1Y Performance:
+74.26%
1-Day Range:
$3.36
$3.535
1-Week Range:
$3.36
$3.66
52-Week Range:
$1.95
$6.23
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.52 | 320.95M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
162.24 | 73.20B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.17 | 41.75B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.32 | 25.29B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.38 | 14.78B | 15.05B | -883.30M | 1.89B | -0.74 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by Stifel Financial Corp - Defense World
State Street Corp Has $7.45 Million Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
State Street Corp Purchases 512,682 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Stifel Financial Corp Sells 301,538 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics’ (AQST) “Buy” Rating Reiterated at HC Wainwright - Defense World
Aquestive receives FDA Orphan Drug Exclusivity for Libervant - MSN
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Aquestive shares reiterated at Buy by analyst as FDA grants ODE to Libervant - Investing.com Canada
Aquestive Therapeutics (NASDAQ:AQST) Receives "Buy" Rating from HC Wainwright - MarketBeat
Analysts Set Expectations for AQST FY2024 Earnings - Defense World
Wellington Management Group LLP Invests $922,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics Gains FDA Orphan Drug Exclusivity for Pediatric Seizure Treatment - Yahoo Finance
Aquestive Therapeutics Receives U.S. FDA Orphan Drug - GlobeNewswire
Cantor Fitzgerald Forecasts AQST FY2024 Earnings - MarketBeat
The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25% - Simply Wall St
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by BNP Paribas Financial Markets - Defense World
Cantor Fitzgerald Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Charles Schwab Investment Management Inc. Purchases 9,268 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics' SWOT analysis: stock poised for growth with innovative epinephrine delivery - Investing.com Canada
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside - Yahoo Finance UK
Aquestive Therapeutics (NASDAQ:AQST) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Aquestive Therapeutics stock initiated at Overweight by Fitzgerald, eyes strong 2025 catalysts - Investing.com UK
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last year - Yahoo Finance
Cantor Fitzgerald Initiates Coverage of Aquestive Therapeutics (AQST) with Overweight Recommendation - MSN
Aquestive Therapeutics (NASDAQ:AQST) shareholders have earned a 88% return over the last year - Simply Wall St
Aquestive Therapeutics' SWOT analysis: oral epinephrine stock poised for growth - Investing.com Nigeria
Aquestive Therapeutics' SWOT analysis: oral epinephrine stock poised for growth By Investing.com - Investing.com South Africa
Oral Thin Films Market Growth in Future Scope 2024-2031 | - openPR
Verition Fund Management LLC Takes $995,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics confirms FDA nod for Anaphylm trial By Investing.com - Investing.com Canada
Aquestive Therapeutics confirms FDA nod for Anaphylm trial - Investing.com
Aquestive Therapeutics Gains FDA Support for Anaphylm - TipRanks
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film - The Manila Times
Aquestive Therapeutics Announces Positive FDA Feedback and - GlobeNewswire
Aquestive's Oral Epinephrine Treatment Advances After Key FDA Feedback for NDA Filing - StockTitan
Aquestive therapeutics COO Jung Cassie sells $214 in stock By Investing.com - Investing.com Nigeria
Aquestive therapeutics COO Jung Cassie sells $214 in stock - Investing.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update - MarketBeat
GSA Capital Partners LLP Acquires 115,223 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Aquestive Therapeutics Inc - GuruFocus.com
Chartwell Investment Partners LLC Buys New Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics, Inc. Announces Board and Committee Changes - Marketscreener.com
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Aquestive Therapeutics to Present at Jefferies and Piper Sandler Healthcare Conferences | AQST Stock News - StockTitan
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):